BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
Lui GYL, et al.
EBioMedicine. 2020 Oct;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub 2020 Sep 11.
EBioMedicine. 2020.
PMID: 32927276
Free PMC article.